Growth Metrics

Whitehawk Therapeutics (WHWK) Income towards Parent Company: 2018-2025

Historic Income towards Parent Company for Whitehawk Therapeutics (WHWK) over the last 7 years, with Sep 2025 value amounting to -$17.7 million.

  • Whitehawk Therapeutics' Income towards Parent Company fell 41.06% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.2 million, marking a year-over-year decrease of 67.25%. This contributed to the annual value of -$63.7 million for FY2024, which is 3.15% up from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' Income towards Parent Company is -$17.7 million, which was up 66.47% from -$52.8 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Income towards Parent Company peaked at -$1.5 million during Q2 2021, and registered a low of -$87.1 million during Q3 2021.
  • Over the past 3 years, Whitehawk Therapeutics' median Income towards Parent Company value was -$16.3 million (recorded in 2023), while the average stood at -$19.2 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first crashed by 2,911.34% in 2021, then surged by 83.38% in 2022.
  • Whitehawk Therapeutics' Income towards Parent Company (Quarterly) stood at -$16.0 million in 2021, then rose by 12.99% to -$13.9 million in 2022, then dropped by 16.93% to -$16.3 million in 2023, then fell by 12.32% to -$18.3 million in 2024, then plummeted by 41.06% to -$17.7 million in 2025.
  • Its Income towards Parent Company stands at -$17.7 million for Q3 2025, versus -$52.8 million for Q2 2025 and -$14.4 million for Q1 2025.